Investor Relations
Corporate Profile
We are a clinical stage biopharmaceutical company focused on delivering transformational medicines to patients with high unmet medical need. Our current focus is on advancing our lead program AKR-001 to provide a powerful new treatment for patients with NASH, a disease for which there are currently no marketed therapies.
Copyright West LLC. Minimum 15 minutes delayed.
November 13, 2019
Akero Therapeutics to Present at the Jefferies 2019 London Healthcare Conference
SAN FRANCISCO , Nov. 13, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-s...
November 12, 2019
Akero Therapeutics Reports Recent Highlights and Third Quarter 2019 Financial Results
SAN FRANCISCO , Nov. 12, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-s...
October 3, 2019
Akero Therapeutics and InSphero partner to evaluate AKR-001 using InSphero's 3D InSight™ Human Liver Disease platform
3D InSight™ Human Liver Disease Platform will be used to screen effects of Akero lead program AKR-00...
September 4, 2019
Akero Therapeutics To Present At The Morgan Stanley 17th Annual Global Healthcare Conference
SAN FRANCISCO , Sept. 4, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-...
August 12, 2019
Akero Therapeutics Reports Recent Highlights and Second Quarter 2019 Financial Results
-- Advanced AKR-001 into Phase 2a BALANCED clinical study in NASH -- -- Raised $98.4 million in aggr...
July 2, 2019
Akero Therapeutics Announces Dosing of First Patient in Phase 2a Study of AKR-001 to Treat NASH (BALANCED)
SAN FRANCISCO , July 2, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-sta...